Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Allows First Over-The-Counter Continuous Glucose Monitor
For the first time, anyone in the United States will soon be able to buy a continuous glucose monitor without a prescription. The Food and Drug Administration authorized Dexcom on Tuesday to start selling a new product, called the Stelo, to adults who do not use insulin. The product is scheduled to hit the market this summer. (Palmer and Lawrence, 3/5)
A Novo Nordisk study showed that its diabetes drug Ozempic lowered the risk that patients with kidney disease would see progression. (Joseph, 3/5)
The failure of Humira’s competitors to gain much traction — so far, at least — helps illustrate the market grip maintained by brand-name drug makers like AbbVie, despite the $84,000-a-year price tag of its wildly successful anti-inflammatory drug. (Weisman, 3/5)
The World Health Organization (WHO) said on Tuesday resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries. (3/5)
The latest trial over claims that Johnson & Johnson's talc products cause cancer ended in a mistrial on Tuesday, as a Florida state court jury said it could not agree on a verdict. (Pierson, 3/5)
Bayer on Tuesday said it won a trial in a lawsuit brought by a retired postal service worker in Pennsylvania who alleged he developed non-Hodgkins lymphoma from using the company's Roundup weedkiller. (Pierson, 3/5)
